成骨细胞与骨髓瘤骨病  

Osteoblasts and myeloma bone disease

作　　者：高珊[1] 付蓉[1] 邵宗鸿[1] 

机构地区：[1]天津医科大学总医院血液科,天津300052

出　　处：《临床血液学杂志》2014年第6期994-997,共4页Journal of Clinical Hematology

基　　金：天津市抗癌重大专项攻关计划(No:12ZCDZSY18000)

摘　　要：骨髓瘤骨病（MBD）是多发性骨髓瘤（MM）最严重的一种并发症,以多发性溶骨病变及进行性骨质破坏等为特征,其机制的关键在于骨髓瘤细胞激活破骨细胞的同时抑制成骨细胞活性,最终导致骨代谢失衡〔1〕。MBD在MM患者中的发生率超过85%。Summary Multiple myeloma （MM） is a kind of plasma malignant tumor. Myeloma bone disease （MBD） is one of the most debilitating manifestations of MM. The recent studies showed that MM cells,bone marrow matrix cells and some cell factors were generated and expressed by osteoblasts and osteoclasts,which could increase osteo- clasts activity and inhibit osteoblasts in the microenvironment of bone marrow. MM patients with osteolytic bone lesions have less osteoblasts and decreased bone formation. The relationship between MM cells and osteoblasts is complicated in MM. It has been demonstrated that Wingless-type （Wnt） signaling, transcription factor Runx2, receptor activator of nuclear factor-κB （RANK） ligand （RANKL） /osteoprotegerin system, IL-3, IL-6, IL-7, TNF-α all involved in the inhibition of osteoblasts in MM. Bortezomib and some other positive regulators of osteoblasts were used in clinic. To increase the positive regulators and decrease the negative ones will be the direction to cure MBD.

关 键 词：多发性骨髓瘤 成骨细胞 骨髓瘤骨病 治疗 

分 类 号：R733.3[医药卫生—肿瘤]